

1626

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C. 20231.

#3



Patricia S. Rocha-Tramaloni

(Print Name)

*[Signature]*

(Signature)

Date: March 08, 2002

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Group No.: 1626

Josef Burg, et al.

Serial No.: 10/014,363

Filed: December 11, 2001

COPY OF PAPERS  
ORIGINALLY FILED

For: ERYTHROPOIETIN CONJUGATES

TRANSMITTAL OF CERTIFIED COPY

March 08, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Attached please find the certified copy of the foreign application from which priority is claimed for this case:

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>
Europe	00127891.0	December 20, 2000

Respectfully submitted,

*[Signature]*

Patricia S. Rocha-Tramaloni  
Attorney for Applicant  
Reg. No. 31054  
Hoffmann-La Roche Inc.  
340 Kingsland Street  
Nutley, New Jersey 07110  
Phone: (973) 235-2441

PSR-T/lad  
Enclosures  
54020





**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr.    Patent application No.    Demande de brevet n°**

00127891.0

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**I.L.C. HATTEN-HECKMAN**

DEN HAAG, DEN  
THE HAGUE,  
LA HAYE, LE

31/10/01





Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der Beschreibung  
Sheet 2 of the certificate  
Page 2 de l'attestation**

Anmeldung Nr.:  
Application no.: 00127891.0  
Demande n°:

Anmeldetag:  
Date of filing: 20/12/00  
Date de dépôt:

Anmelder:  
Applicant(s):  
Demandeur(s):  
F. HOFFMANN-LA ROCHE AG  
4070 Basel  
SWITZERLAND

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:  
Erythropoietin conjugates

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:  
State:  
Pays:

Tag:  
Date:  
Date:

Aktenzeichen:  
File no.  
Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:  
/

Am Anmeldetag benannte Vertragsstaaten:  
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques:



F. Hoffmann-La Roche AG, CH-4070 Basle, Switzerland

EPO - Munich  
3

Case 20805

20. Dez. 2000

### ERYTHROPOIETIN CONJUGATES

5

#### BACKGROUND OF THE INVENTION

Erythropoiesis is the production of red blood cells, which occurs to offset cell destruction. Erythropoiesis is a controlled physiological mechanism that enables sufficient red blood cells to be available for proper tissue oxygenation. Naturally occurring human erythropoietin (EPO) is produced in the kidney and is the humoral plasma factor which stimulates red blood cell production (Carnot, P and Deflandre, C (1906) C.R. Acad. Sci. 143: 432; Erslev, AJ (1953 Blood 8: 349; Reissmann, KR (1950) Blood 5: 372; Jacobson, LO, Goldwasser, E, Freid, W and Plzak, LF (1957) Nature 179: 6331-4). Naturally occurring EPO stimulates the division and differentiation of committed erythroid progenitors in the bone marrow and exerts its biological activity by binding to receptors on erythroid precursors (Krantz, BS (1991) Blood 77: 419).

Erythropoietin has been manufactured biosynthetically using recombinant DNA technology (Egrie, JC, Strickland, TW, Lane, J et al. (1986) Immunobiol. 72: 213-224) and is the product of a cloned human EPO gene inserted into and expressed in the ovarian tissue cells of the Chinese hamster (CHO cells). The primary structure of the predominant, fully processed form of human erythropoietin (hEPO) is illustrated in Fig. 1. There are two disulfide bridges between Cys<sup>7</sup>-Cys<sup>161</sup> and Cys<sup>29</sup>-Cys<sup>33</sup>. The molecular weight of the polypeptide chain of EPO without the sugar moieties is 18,236 Da. In the intact EPO molecule, approximately 40% of the molecular weight are accounted for by the carbohydrate groups that glycosylate the protein at glycosylation sites on the protein (Sasaki, H, Bothner, B, Dell, A and Fukuda, M (1987) J. Biol. Chem. 262: 12059).

WH/19.12.2000

- 2 -

Because human erythropoietin is essential in red blood cell formation, the hormone is useful in the treatment of blood disorders characterised by low or defective red blood cell production. Clinically, EPO is used in the treatment of anemia in chronic renal failure patients (CRF) (Eschbach, JW, Egri, JC, Downing, MR et al. (1987) NEJM 316: 73-78; Eschbach, JW, Abdulhadi, MH, Browne, JK et al. (1989) Ann. Intern. Med. 111: 992; Egrie, JC, Eschbach, JW, McGuire, T, Adamson, JW (1988) Kidney Intl. 33: 262; Lim, VS, Degowin, RL, Zavala, D et al. (1989) Ann. Intern. Med. 110: 108-114) and in AIDS and cancer patients undergoing chemotherapy (Danna, RP, Rudnick, SA, Abels, RI In: MB, Garnick, ed. Erythropoietin in Clinical Applications-An International Perspective. New York, NY: Marcel Dekker; 1990: p. 301-324). However, the bioavailability of commercially available protein therapeutics such as EPO is limited by their short plasma half-life and susceptibility to protease degradation. So, for example, pegylated EPO derivatives have been proposed to overcome these disadvantages.

Common routes to pegylated proteins yield mixtures mono- and oligo-pegylated proteins. Moreover, the polyethylene glycol compound (PEG) is bound at several positions of the proteins depending in the amount and reactivities of the available reactive groups on the protein surface. Such a mixture may result in severe shortcomings: PEG may be bound at positions which interact with the protein specific receptor and conclusively reduce or even prohibit therapeutic efficacy. To solve this drawback either separation and purification of active ingredients of such a mixture or a selective synthetic route to avoid formation is required. Clearly avoiding any formation of mixtures makes it easier to receive a pure active pharmaceutical ingredient in terms of a single positional isomer in essentially higher yields. Separation of positional isomers of PEG-protein mixtures may even be impossible with common tools in production scale.

Several methods have been proposed for the selective modification of recombinantly produced polypeptides.

European Patent Application EP 651,761 discloses the selective modification of recombinantly produced polypeptides at terminal  $\alpha$ -carbon reactive groups. The first step in the method is to form a recombinantly produced polypeptide so that it is protected at the terminal  $\alpha$ -carbon reactive group with a biologically added protecting group. The biologically added protecting group is preferably an amino acid, peptide and/or polypeptide that contains at least one site that is cleavable enzymatically or chemically, and preferably has a sequence that is not present in the sequence of the desired polypeptide. Once formed the biologically protected polypeptide is reacted with chemical protecting agents to protect the side chain groups and then is cleaved with a cleavage reagent specific



- 3 -

for the biologically added protecting group. By these means a polypeptide is produced having an unprotected N-terminal amino group and protected side chain reactive groups. The unprotected N-terminal amino group is modified with a modifying agent to form an N-terminally modified and side-chain-protected polypeptide. It is then deprotected to  
5 form an N-terminally modified polypeptide. EP 651,761 teaches that any sequence of amino acids may be attached as biologically added protecting groups. However, in mammalian expression systems EPO is expressed with a leader signal sequence which is cleaved off by a signal peptidase in order to yield the processed, mature EPO. Such signal peptidases recognise only restricted amino acid residues at the P1' and P3' cleavage site  
10 (R. E. Dalbey et al. Protein Sci. 6, 1129 (1997)). Conclusively, a biologically added protecting peptide has to be built up from an N-terminal amino acid sequence of at least three amino acids for cleavage of the signal sequence, followed by an amino acid sequence for enzymatic or chemical removal of the protecting group. If the recognition sequences of both the signal peptidase and the cleavage protease are identical or closely related then the  
15 sequence of the biologically added protecting group can be reduced to a few amino acids.

Further, N-terminal selective modification was achieved by chemoselective ligation to an aldehyde (or ketone)-functionalized target macromolecule (European Patent Application EP 788,375; Gaertner, HF, Offord, RE, Bioconjugate Chem., 7 (1), 38 -44 (1996)). However, this method only works for N-terminal serines or threonines.

20 Selective modification at N-terminal alanine was demonstrated by transamination of alanine to pyruvate (European Patent Applications EP 964,702 and EP 605,963). Disadvantage of this method is that the formed EPO derivative showed a reduced in vitro activity. Also the transformation agents  $\text{Cu}^{2+}$ /glyoxylic acid/NaOAc are likely to produce side reactions within the EPO molecule.

25 Site specific N-terminal modification was also shown by transglutaminase-mediated incorporation of poly(ethylene glycol) derivatives (Sato, H., Yamamoto, K, Hayashi, E, Takahara, Y, Bioconjugate Chem. 11(4), 502-509 (2000)). But this method showed only low yields and needs incorporation of a peptide tag at the N-terminus and hence modifies the polypeptide structure.

30 Modification with glyoxylyl-based labelling reagents also enables selective N-terminal modification (Zhao, ZG, Im, JS, Clarke, DF, Bioconjugate Chem. 10, 424 - 430 (1999)) but is restricted to cysteine.

- 4 -

## SUMMARY OF THE INVENTION

This invention provides an erythropoietin conjugate, said conjugate comprising an erythropoietin glycoprotein having an N-terminal  $\alpha$ -amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and  
 5 analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula



10 with the -CO of the poly(ethylene glycol) group forming an amide bond with said N-terminal  $\alpha$ -amino group; wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to about 1350.

Compared to unmodified EPO (i.e., EPO without a PEG attached) and conventional PEG-EPO conjugates, the present conjugates have an increased circulating half-life and  
 15 plasma residence time, decreased clearance, and increased clinical activity *in vivo*. The conjugates of this invention have the same uses as EPO. In particular, the conjugates of this invention are useful to treat patients by stimulating the division and differentiation of committed erythroid progenitors in the bone marrow in the same way EPO is used to treat patients.

20

## DETAILED DESCRIPTION OF THE INVENTION

This invention provides conjugates, said conjugate comprising an erythropoietin glycoprotein having an N-terminal  $\alpha$ -amino group and having the *in vivo* biological  
 25 activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula

30



with the -CO -CO (i.e. carbonyl) of the poly(ethylene glycol) group forming an amide bond with said N-terminal  $\alpha$ -amino group; wherein R is lower alkyl; x is 2 or 3; and m is

- 5 -

from about 450 to about 1350; i.e.  $m$  is chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from about 20 kDa (kilodaltons) to about 60 kDa.

It has been found that the conjugates of this invention can be used in the same manner as unmodified EPO. However, the conjugates of this invention have an increased circulating half-life and plasma residence time, decreased clearance, and increased clinical activity *in vivo*. Because of these improved properties, the conjugates of this invention can be administered once weekly instead of the three times weekly for unmodified EPO. Decreased frequency of administration is expected to result in improved patient compliance leading to improved treatment outcomes, as well as improved patient quality of life. Compared to conventional conjugates of EPO linked to poly(ethylene glycol) it has been found that conjugates having the molecular weight and linker structure of the conjugates of this invention have an improved potency, stability, area under the curve (AUC), and circulating half-life.

The term "N-terminal  $\alpha$ -amino group" refers to the N-terminal amino residue of a peptide, i.e. that end of a peptide or protein chain having an amino acid with a free  $\alpha$ -amino ( $\text{NH}_2$ -) group.

The term "erythropoietin" or "EPO" refers to a glycoprotein, having the amino acid sequence set out in Fig. 1 or Fig. 2, preferably in Fig. 1, or an amino acid sequence substantially homologous thereto, whose biological properties relate to the stimulation of red blood cell production and the stimulation of the division and differentiation of committed erythroid progenitors in the bone marrow. As used herein, these terms include such proteins modified deliberately, as for example, by site directed mutagenesis or accidentally through mutations. These terms also include analogs having from 1 to 6 additional sites for glycosylation, analogs having at least one additional amino acid at the carboxy terminal end of the glycoprotein, wherein the additional amino acid includes at least one glycosylation site, and analogs having an amino acid sequence which includes a rearrangement of at least one site for glycosylation. These terms include both natural and recombinantly produced human erythropoietin.

The term "intermediate EPO" refers to an erythropoietin glycoprotein derivative with a N-terminal extension. Preferably the amino acid extension comprises a secretion signal sequence, optionally followed by a purification tag, e.g. histidine tag (as described for example in H. M. Sassenfeld, Trends in Biotechnol. 8, 88 – 93 (1990)), followed by an

- 6 -

enzyme recognition sequence for digestion of a protein which is followed by the erythropoietin glycoprotein amino acid sequence as defined below.


The term "modified EPO" refers to an intermediate EPO wherein the secretion signal has been cleaved off, e.g. to an EPO glycoprotein which is extended at the N-terminus by a proteolytic cleavage site, e.g. the sequence APPRIEGR, i.e. APPRIEGR-EPO, or APP, i.e. APP-EPO, or APPGAAHY, i.e. APPGAAHY-EPO or a sequence substantially homologous thereto (see also Figures 3, 4 and 5).

The term "protected modified EPO" refers to a modified EPO, which is received by acylation of  $\epsilon$ -amino groups with chemical protecting agents, e.g. by citraconylation.

The term "protected EPO" means the EPO derivative which is obtained after proteolytic cleavage of the protected modified EPO, i.e. EPO wherein the  $\epsilon$ -amino groups have been modified with chemical protecting agents and wherein there is a free N-terminal  $\alpha$ -amino group.

The term "homologous amino acid sequence" means that the corresponding amino acid sequences have at least 80% amino acid sequence identity with the corresponding proteolytic cleavage sequences or the corresponding erythropoietin amino acids shown in Fig. 1 or 2 and show the required biological activity (either cleavable by the corresponding protease or having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells in the case of the pegylated erythropoietin compounds as defined in the description and claims. Preferably, the homology is 90%, more preferably 95%.

The erythropoietin conjugates of this invention can be represented by Formula 1:



wherein x, m and R are as above. In Formula I, P is the residue of an erythropoietin glycoprotein described herein, (i.e. without the N-terminal  $\alpha$ -amino group which forms an amide linkage with the carbonyl shown in Formula I), having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells.

In a preferred embodiment of the present invention R is methyl. Preferably, m is from about 550 to about 1000, more preferably from about 650 to about 750.

- 7 -

In the most preferred embodiment of the present invention R is methyl, and m is from about 650 to about 750, i.e. the conjugate as defined above having the formula



wherein m is from 650 to 750 and P is as defined above. Preferably m has an average of  
5 about 730.

Preferably, the glycoprotein of the conjugates as defined above is a human erythropoietin. Human erythropoietin and analogous proteins as defined above can be expressed by endogenous gene activation. Preferred human erythropoietin glycoproteins are those shown in Fig. 1 or 2, most preferably those shown in Fig. 1.

10 Further, P may be selected from the group consisting of residues of human erythropoietin and analogs thereof having from 1 to 6 additional sites for glycosylation. As set out in detail below, the preparation and purification of EPO are well known in the art. By EPO is meant the natural or recombinant protein, preferably human, as obtained from  
15 any conventional source such as tissues, protein synthesis, cell culture with natural or recombinant cells. Any protein having the activity of EPO, such as muteins or otherwise modified proteins, is encompassed. Recombinant EPO may be prepared via expression in CHO, BHK, COS, HeLa or PER.C6 cell lines or other appropriate cell lines of animal or human origin, by recombinant DNA technology or by endogenous gene activation. Expression of proteins, including EPO, by endogenous gene activation is well known in the  
20 art and is disclosed, for example in U.S. Patents Nos. 5,733,761, 5,641,670, and 5,733,746, and international patent publication Nos. WO 93/09222, WO 94/12650, WO 95/31560, WO 90/11354, WO 91/06667 and WO 91/09955, the contents of each of which are incorporated herein by reference. The preferred EPO species for the preparation of erythropoietin glycoprotein products are human EPO species. More preferably, the EPO  
25 species is the human EPO having the amino acid sequence set out in Fig. 1 or Fig. 2, more preferably the amino acid sequence set out in Fig. 1.

In an embodiment, P may be the residue of a glycoprotein analog having from 1 to 6 additional sites for glycosylation. Glycosylation of a protein, with one or more  
30 oligosaccharide groups, occurs at specific locations along a polypeptide backbone and greatly affects the physical properties of the protein such as protein stability, secretion, subcellular localisation, and biological activity. Glycosylation is usually of two types. O-linked oligosaccharides are attached to serine or threonine residues and N-linked oligosaccharides are attached to asparagine residues. One type of oligosaccharide found on both N-linked and O-linked oligosaccharides is N-acetylneuraminic acid (sialic acid),

- 8 -

which is a family of amino sugars containing 9 or more carbon atoms. Sialic acid is usually the terminal residue on both N-linked and O-linked oligosaccharides and, because it bears a negative charge, confers acidic properties to the glycoprotein. Human erythropoietin, having 165 amino acids, contains three N-linked and one O-linked oligosaccharide chains which comprise about 40% of the total molecular weight of the glycoprotein. N-linked glycosylation occurs at asparagine residues located at positions 24, 38, and 83 and O-linked glycosylation occurs at a serine residue located at position 126. The oligosaccharide chains are modified with terminal sialic acid residues. Enzymatic removal of all sialic acid residues from the glycosylated erythropoietin results in loss of *in vivo* activity but not *in vitro* activity because sialylation of erythropoietin prevents its binding, and subsequent clearance, by hepatic binding protein.

The glycoproteins of the present invention include analogs of human erythropoietin with one or more changes in the amino acid sequence of human erythropoietin which result in an increase in the number of sites for sialic acid attachment. These glycoprotein analogs may be generated by site-directed mutagenesis having additions, deletions, or substitutions of amino acid residues that increase or alter sites that are available for glycosylation. Glycoprotein analogs having levels of sialic acid greater than those found in human erythropoietin are generated by adding glycosylation sites which do not perturb the secondary or tertiary conformation required for biological activity. The glycoproteins of the present invention also include analogs having increased levels of carbohydrate attachment at a glycosylation site which usually involve the substitution of one or more amino acids in close proximity to an N-linked or O-linked site. The glycoproteins of the present invention also include analogs having one or more amino acids extending from the carboxy terminal end of erythropoietin and providing at least one additional carbohydrate site. The glycoproteins of the present invention also include analogs having an amino acid sequence which includes a rearrangement of at least one site for glycosylation. Such a rearrangement of glycosylation site involves the deletion of one or more glycosylation sites in human erythropoietin and the addition of one or more non-naturally occurring glycosylation sites. Increasing the number of carbohydrate chains on erythropoietin, and therefore the number of sialic acids per erythropoietin molecules may confer advantageous properties such as increased solubility, greater resistance to proteolysis, reduced immunogenicity, increased serum half-life, and increased biological activity. Erythropoietin analogs with additional glycosylation sites are disclosed in more detail in European Patent Application 640 619, to Elliot published March 1, 1995.

- 9 -

In a preferred embodiment, the glycoproteins of the present invention comprise an amino acid sequence which includes at least one additional site for glycosylation such as, but not limited to, erythropoietins comprising the sequence of human erythropoietin modified by a modification selected from the following:

5                   Asn<sup>30</sup>Thr<sup>32</sup>;  
                   Asn<sup>51</sup>Thr<sup>53</sup>;  
                   Asn<sup>57</sup>Thr<sup>59</sup>;  
                   Asn<sup>69</sup>;  
                   Asn<sup>69</sup>Thr<sup>71</sup>;  
 10               Ser<sup>68</sup>Asn<sup>69</sup>Thr<sup>71</sup>;  
                   Val<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;  
                   Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;  
                   Ser<sup>87</sup>Asn<sup>88</sup>Gly<sup>89</sup>Thr<sup>90</sup>;  
                   Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>Thr<sup>92</sup>;  
 15               Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>Ala<sup>162</sup>;  
                   Asn<sup>69</sup>Thr<sup>71</sup>Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;  
                   Asn<sup>30</sup>Thr<sup>32</sup>Val<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;  
                   Asn<sup>89</sup>Ile<sup>90</sup>Thr<sup>91</sup>;  
                   Ser<sup>87</sup>Asn<sup>89</sup>Ile<sup>90</sup>Thr<sup>91</sup>;  
 20               Asn<sup>136</sup>Thr<sup>138</sup>;  
                   Asn<sup>138</sup>Thr<sup>140</sup>;  
                   Thr<sup>125</sup>; and  
                   Pro<sup>124</sup>Thr<sup>125</sup>.

25               The notation used herein for modification of amino acid sequence means that the position(s) of the corresponding unmodified protein (e.g. hEPO of Fig. 1 and Fig. 2) indicated by the superscripted number(s) is changed to the amino acid(s) that immediately precede the respective superscripted number(s).

30               The glycoprotein may also be an analog having an amino acid sequence which includes a rearrangement of at least one site for glycosylation. The rearrangement may comprise a deletion of any of the N-linked carbohydrate sites in human erythropoietin and an addition of an N-linked carbohydrate site at position 88 of the amino acid sequence of human erythropoietin. Preferably, the glycoprotein is an analog selected from the group consisting of Gln<sup>24</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO; Gln<sup>38</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO; and Gln<sup>83</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup> EPO.

- 10 -

As used herein, "lower alkyl" means a linear or branched alkyl group having from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl and isopropyl. In accordance with this invention, R is any lower alkyl. Conjugates in which R is methyl are preferred.

5        The symbol "m" represents the number of ethylene oxide residues ( $\text{OCH}_2\text{CH}_2$ ) in the poly(ethylene oxide) group. A single PEG subunit of ethylene oxide has a molecular weight of about 44 daltons. Thus, the molecular weight of the conjugate (excluding the molecular weight of the EPO) depends on the number "m". In the conjugates of this invention "m" is from about 450 to about 1350 (corresponding to a molecular weight of  
10        about 20 kDa to about 60 kDa), preferably from about 650 to about 750 (corresponding to a molecular weight of about 30 kDa), most preferably about 730. The number m is selected such that the resulting conjugate of this invention has a physiological activity comparable to unmodified EPO, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified EPO. A molecular weight of "about" a  
15        certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques. The number "m" is selected so that the molecular weight of the poly(ethylene glycol) chain covalently linked to the erythropoietin glycoprotein is from about 20 kDa to about 60 kDa, and is preferably about 32 kDa.

20        The steps of the method for the preparation of the above compounds involve forming a recombinant single copy erythropoietin glycoprotein or a portion thereof so that the single copy glycoprotein is protected with one or more biologically added protecting groups at the N-terminal  $\alpha$ -amine. The recombinant erythropoietin can then be reacted with a protecting agent to selectively protect reactive side chain amino groups and thereby prevent amino side chains groups from being modified with the pegylation reagent. The  
25        erythropoietin glycoprotein can be cleaved with at least one cleavage reagent specific for the biological protecting group to form an unprotected terminal amino acid  $\alpha$ -carbon reactive amino group. The unprotected terminal amino acid  $\alpha$ -carbon reactive group may be modified with a pegylation reagent. The side chain protected terminally modified erythropoietin glycoprotein is then deprotected at the side chain groups to form a  
30        terminally modified (= pegylated) recombinant erythropoietin glycoprotein.


Therefore, the invention also refers to a process comprising

- a) expression and, preferably serumfree fermentation, of a recombinant EPO protein comprising a N-terminal peptidic extension which comprises a proteolytic cleavage site



- b) protecting the  $\epsilon$ -amino groups,
- c) proteolytic cleavage of the N-terminal peptidic extension,
- d) pegylation of the N-terminal  $\alpha$ -amino group,
- e) deprotection of the  $\epsilon$ -amino groups of the erythropoietin glycoprotein,
- f) wherein optionally each of the above steps may be followed by a purification step.

The invention also relates to the above process wherein the recombinant EPO comprises a sequence selected from the group consisting of the amino acid sequences shown in Figures 1 to 5. The  $\epsilon$ -amino groups may be protected by a citraconylation and the N-terminal  $\alpha$ -amino group may be pegylated with



in which  $R$  and  $m$  are as defined above.

In more detail, the above steps may be performed as follows:

#### A) Expression, fermentation and purification of modified EPO :

15 Cloning and expression methods for EPO and EPO related molecule are known in the art. Human erythropoietin (EPO) is a human glycoprotein which stimulates the formation of erythrocytes. Its preparation and therapeutic application are described in detail for example in U.S. Patent Nos. 5,547,933 and 5,621,080, EP-B 0 148 605, Huang, S.L., Proc. Natl. Acad. Sci. USA (1984) 2708-2712, EP-B 0 205 564, EP-B 0 209 539 and EP-  
20 B 0 411 678 as well as Lai, P.H. et al., J. Biol. Chem. 261 (1986) 3116-3121, an Sasaki, H. et al., J. Biol. Chem. 262 (1987) 12059-12076. Erythropoietin for therapeutic uses may be produced by recombinant means (EP-B 0 148 605, EP-B 0 209 539 and Egrie, J.C., Strickland, T.W., Lane, J. et al. (1986) Immunobiol. 72: 213-224).

Methods for the expression and preparation of erythropoietin in serum free medium  
25 are described for example in WO 96/35718, to Burg published 14 November 1996, and in  
European Patent Publication No. 513 738, to Koch published 12 June 1992. In addition to  
the publications mentioned above, it is known that a serum-free fermentation of  
recombinant CHO cells which contain an EPO gene can be carried out. Such methods are  
described for example in EP-A 0 513 738, EP-A 0 267 678 and in a general form by  
30 Kawamoto, T. et al., Analytical Biochem. 130 (1983) 445-453, EP-A 0 248 656, Kowar, J.

- 12 -

and Franek, F., Methods in Enzymology 421 (1986) 277-292, Bavister, B., Exp. Zoology 271 (1981) 45-51, EP-A 0 481 791, EP-A 0 307 247, EP-A 0 343 635, WO 88/00967.

Purification methods for the erythropoietin and derivatives thereof are also known in the art:

- 5 In EP-A 0 267 678 an ion exchange chromatography on S-Sepharose, a preparative reverse phase HPLC on a C<sub>8</sub> column and a gel filtration chromatography are described for the purification of EPO produced in serum-free culture after dialysis. In this connection the gel filtration chromatography step can be replaced by ion exchange chromatography on S-Sepharose fast flow. It is also proposed that a dye chromatography on a Blue Trisacryl  
10 column be carried out before the ion exchange chromatography.

- A process for the purification of recombinant EPO is described by Nobuo, I. et al., J. Biochem. 107 (1990) 352-359. In this process EPO is treated however with a solution of Tween<sup>®</sup> 20, phenylmethylsulfonyl fluoride, ethylmaleimide, pepstatin A, copper sulfate and oxamic acid prior to the purification steps. Publications, including WO 96/35718, to  
15 Burg published 14 November 1996, discloses a process for preparing erythropoietin in a serum free fermentation process (EPOsf).

**B) Reaction with a protecting agent to selectively protect reactive side chain amino groups: Preparation of protected modified EPO**

- 20 Suitable chemical protecting agents form bonds at unprotected side chain amines and are less stable than and different from those bonds at the N-terminus. Plenty of chemical protecting agents are known (see for example European Patent Application EP 651,761). Preferred are cyclic dicarboxylic acid anhydrides like maleic or citraconylic anhydrides.

- 25 Citraconylation is the preferred method if the target polypeptide or fusion protein (herein termed modified EPO) properties accept slightly alkaline conditions for protection and acidic conditions for deprotection (Dixon, HBF; Perham, RN : Biochem. J. 109(2), 312 - 14 (1968); Atassi, MZ, Habeeb, AFSA: Methods Enzymol. 25(Pt. B), 546 - 53 (1972)).

- Optionally the protected modified EPO may be purified before performing the next  
30 step.

- 13 -

Proteolytic cleavage of protected modified EPO: Preparation of protected EPO

Suitable proteases for cleavage of fusion proteins are described by Carter, P: Site-specific proteolysis of fusion proteins. in Protein Purification: From Molecular Mechanisms to Large Scale Processes, ACS, Washington DC, pp. 181 - 193 (1990). Such  
5 proteases require a narrow specificity to cleave selectively at their recognition sequence and not anywhere in the target protein sequence. Examples are factor Xa which cleaves at IEGR↓ and enterokinase which cleaves at DDDDK↓. Moreover enterokinase is reported to cleave DDDDK↓AP which indicates specificity at the P1' and P2' site for interleukins (P. Carter). Enterokinase is, however, not preferred if chemical protecting agents to protect the  
10 side chain ε-amino groups of lysines have to be introduced. In this case the enzyme would not work any more at the wanted cleaving site.

Among others IgA protease is of use which cleaves preferentially at PP↓XP (X = T, S, A). The XP sequence makes it suitable for interleukins and erythropoietin (EP513073). Another suitable protease is a subtilisin BPN' variant (Genenase™, Genencor Int. Inc.)  
15 which cleaves at HY↓.


Optionally the protected EPO protein may be purified at this stage.

D) Modification with a pegylation reagent:

Human EPO contains nine free amino groups, the amino-terminal amino group  
20 plus the ε-amino groups of 8 lysine residues. When the pegylation reagent is a SBA compound of Formula II, it has been found that at pH 7.5, a protein:PEG ratio of 1:3, and a reaction temperature of from 20-25°C, a mixture of mono-, di-, and trace amounts of the tri-pegylated species are produced if it is reacted with EPO. The pegylated EPO can be administered as a mixture, or as the cation exchange chromatography separated different  
25 pegylated species. By manipulating the reaction conditions (e.g., ratio of reagents, pH, temperature, protein concentration, time of reaction etc.), the relative amounts of the different pegylated species can be varied.

Using the procedures as specified herein for protected EPO only the N-terminal α-amino group of the N-terminal alanine of the protected EPO is pegylated. Because of  
30 protection of all of the ε-amino groups of the lysine side chains neither di-, nor oligo-pegylated protected EPOs are formed

The compound of Formula I can be prepared from the known polymeric material:



in which R and m are as described above, by condensing the compound of Formula II with the erythropoietin glycoprotein of step c). Compounds of Formula II in which x is 3 are  
5 alpha-lower alkoxy, butyric acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SBA). Compounds of Formula II in which x is 2 are alpha-lower alkoxy, propionic acid succinimidyl esters of poly(ethylene glycol) (lower alkoxy-PEG-SPA). Any conventional method of reacting an activated ester with an amine to form an amide can be utilised. In the reaction described above, the exemplified succinimidyl ester is a leaving  
10 group causing the amide formation. The use of succinimidyl esters such as the compounds of formula II to produce conjugates with proteins are disclosed in U.S. Patent No. 5,672,662, issued September 30, 1997 (Harris, et al.).

The pegylation reaction may be performed at a molar ratio of 1:5 (EPO to PEG-SBA reagent) at a final protein concentration of 5 mg/ml. The preferred pegylation reagent is a methoxy-PEG-SBA, which is a compound of Formula II in which R is methyl; x is 3; and m is from 650 to 750 (average about 730, corresponding to an average molecular weight of about 32 kDa, methoxy-PEG-SBA is commercially available: Shearwater Polymers, Inc.).

Purification of the reaction product from the reaction mixture may be achieved by conventional chromatographic purification as described in the Examples.

**E) Deprotection of ε-amino groups (side chain amino groups):**

Cleavage of the protection agents may be achieved by conventional methods (see above). In case of decitraconylation, deprotection of the protein may be achieved by stirring the solution at a low pH, e.g. 2.5 for 5 h at ambient temperature. The reaction may be stopped by adjusting the pH to 4.5 with sodium hydroxide and the solution is stored frozen at -20°C until ready for purification.

Purification of the reaction product from the reaction mixture may be achieved by conventional chromatographic purification as described in the Examples.

- 15 -

The specific activity of EPO or EPO conjugates in accordance with this invention can be determined by various assays known in the art. The biological activity of the purified EPO proteins of this invention are such that administration of the EPO protein by injection to human patients results in bone marrow cells increasing production of reticulocytes and red blood cells compared to non-injected or control groups of subjects. The biological activity of the EPO proteins, or fragments thereof, obtained and purified in accordance with this invention can be tested by methods according to Annable, et al., Bull. Wld. Hlth. Org. (1972) 47: 99-112 and Pharm. Europa Spec. Issue Erythropoietin BRP Bio 1997(2). Another biological assay for determining the activity of EPO protein, the normocythaemic mouse assay, is described in Example 4.

The conjugates in accordance of this invention can be administered in a therapeutically effective amount to patients in the same way EPO is administered. The therapeutically effective amount is that amount of conjugate necessary for the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells. The exact amount of conjugate is a matter of preference subject to such factors as the exact type of condition being treated, the condition of the patient being treated, as well as the other ingredients in the composition. For example, 0.01 to 10 µg per kg body weight, preferably 0.1 to 3 µg per kg body weight, may be administered e.g. once weekly.

The invention also refers to the corresponding pharmaceutical compositions comprising a conjugate as described above and a pharmaceutically acceptable excipient.

The pharmaceutical compositions containing the conjugate may be formulated at a strength effective for administration by various means to a human patient experiencing blood disorders characterised by low or defective red blood cell production. Average therapeutically effective amounts of the conjugate may vary and in particular should be based upon the recommendations and prescription of a qualified physician.

The erythropoietin glycoprotein products prepared in accordance with this invention may be prepared in pharmaceutical compositions suitable for injection with a pharmaceutically acceptable carrier or vehicle by methods known in the art. For example, appropriate compositions have been described in WO97/09996, WO97/40850, WO98/58660, and WO99/07401. For example, the compounds of the present invention may be formulated in 10 mM sodium/potassium phosphate buffer at pH 7 containing a tonicity agent, e.g. 132 mM sodium chloride. Optionally the pharmaceutical composition

- 16 -

may contain a preservative. The pharmaceutical composition may contain different amounts of erythropoietin, e.g. 10 – 10000 µg/ml, e.g. 50 µg/ml or 400 µg/ml.

Preferably, the pharmaceutical composition comprises a conjugate as defined above, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to  
 5 keep the solution pH in the range from about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable excipients, e.g. the composition comprises about 10 µg to about 10000 µg erythropoietin conjugate per ml, 10 – 200 mmol/l sulfate, about 10 to about 50 mmol/l phosphate pH 6.0 to 6.5, optionally up to 1 mM CaCl<sub>2</sub> and optionally about 1 – 5 % of a polyol. Examples for suitable compositions are:

- 10 a) 50 µg/ml or 400 µg/ml erythropoietin conjugate, 10 mM sodium/potassium phosphate, 100 mM NaCl, pH 7.0,
- b) 50 µg/ml or 400 µg/ml erythropoietin conjugate, 10 mM sodium phosphate, 120 mM sodium sulfate, pH 6.2,
- c) 50 µg/ml or 400 µg/ml erythropoietin conjugate, 10 mM sodium phosphate,  
 15 40 mM sodium sulfate, 3% mannitol, pH 6.2,
- d) 50 µg/ml or 400 µg/ml erythropoietin conjugate, 10 mM sodium phosphate, 40 mM sodium sulfate, 3% mannitol, 7.5 µM CaCl<sub>2</sub>, pH 6.2,
- e) 50 µg/ml or 400 µg/ml erythropoietin conjugate, 50 mM arginine, 100 mM sodium sulfate, 1 mM CaCl<sub>2</sub>, pH 6.2, and
- 20 f) 50 µg/ml or 400 µg/ml erythropoietin conjugate, 50 mM arginine, 30 mM sodium sulfate, 3% mannitol, 1 mM CaCl<sub>2</sub>, pH 6.2.

The conjugates of the present invention are especially useful for the preparation of medicaments for the treatment or prophylaxis of diseases correlated with anemia in chronic renal failure patients (CRF), AIDS and for the treatment of cancer patients  
 25 undergoing chemotherapy.

The invention also refers to the use of a conjugate as defined above for the preparation of medicaments, especially for the preparation of medicaments for the treatment or prophylaxis of diseases correlated with anemia in chronic renal failure patients (CRF), AIDS and for the treatment of cancer patients undergoing chemotherapy.

30 An additional embodiment of the present invention refers to a method for the prophylactic and/or therapeutic treatment of disorders involving anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy comprising the step of administering to a patient a conjugate as described above.

- 17 -

The invention refers also to compounds as defined above for the treatment of diseases which are associated with anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy.

Another aspect of the present invention comprises the above compounds whenever  
5 prepared by a process as described above.

A further embodiment of the invention refers to erythropoieting lycoproteins comprising the amino acid sequences as shown in Fig. 1 and Fig. 2 having a N-terminal peptidic extension which represents a proteolytic cleavage site, optionally comprising a N-terminal purification tag. Examples for these peptides are APPRIEGR-EPO, APP-EPO and  
10 APPGAAHY-EPO (see also Fig. 3 to 5). One embodiment of the invention refers to erythropoietin glycoproteins comprising the amino acid sequences as shown in Figures 3 to 5.

The invention will be better understood by reference to the following examples  
15 which illustrate but do not limit the invention described herein.

- 18 -

EXAMPLESEXAMPLE 1: Expression, fermentation and purification of modified EPO5 (1) Expression of modified-EPO Constructs

## a) Reagents

Unless specified, all biochemical reagents used were from Roche Diagnostics GmbH (Mannheim, Germany), and all cell culture reagents from Gibco-BRL (Eggenstein, Germany).

10

## b) Cloning of the wildtype EPO expression construct.

For stable expression in Chinese Hamster Ovary (CHO) cells, standard eukaryotic expression vectors such as pcDNA3 (Invitrogen BV, Groningen, Netherlands), pCI-neo (Promega, Madison, WI, USA) were modified by substituting the *neo* gene coding for  
15 G418-resistance with the gene coding for mice dihydrofolate reductase (DHFR, Crouse *et al.* J. Biol. Chem. 257, 7887 – 7897 (1982)), whose expression level is controlled by the simian virus 40 (SV40) early promoter and its late polyadenylation signal. In case of pcDNA3 the resulting vector was designated p. 11381 (M. Tacke *et al.* Hepatology 26, 1626 – 1633 (1997)).

20 The wildtype erythropoietin coding fragment is obtainable according to methods known in the art, e.g. as described by Jacobs K. *et al.*, Nature 313, 806-10 (1985). Preferably, the coding fragment is amplified using primers EPO-EcoRI 5'-GAGCCTGAATTCACCACC and EPO-SalI 5'-AGGTGGGTCGACCTGGTCATCTGTCCCCTG. The PCR fragment was digested with  
25 EcoRI and SalI (sites are underlined in primer sequences) and cloned into the multiple cloning site of the predigested pCI-dhfr vector fragment. Expression of the EPO gene is therefore under control of the human cytomegalovirus (CMV) immediate-early enhancer/promoter region, an optimized chimeric intron for regulated expression and the SV40 late polyadenylation signal.

30



- 19 -

## c) Cloning of APPRIEGR-EPO expression construct

The APPRIEGR peptide was assembled as a NarI DNA fragment by two annealed oligonucleotides APPRIEGRfor, 5'-CGCCCCCCCCCGAATCGAGGGCCG, and APPRIEGRrev, 5'-CGCGGGCCCTCGATTCTGGGGGGGGG (remnants of NarI site underlined), and cloned in between the N-terminal signal sequence and the mature EPO coding region.

## d) Cloning of APP-EPO expression construct

The APP peptide was assembled as a NarI DNA fragment by two annealed oligonucleotides APPfor, 5'-CGCCCCCCC, and APPrev, 5'-CGGGGGGGG (remnants of NarI site underlined), and cloned in between the N-terminal signal sequence and the mature EPO coding region.

## e) Cloning of APPGAAHY-EPO expression construct

The APPGAAHY peptide was assembled as a NarI DNA fragment by two annealed oligonucleotides APPGAAHYfor, 5'-CGCCCCCCCCCGGCGCCGCCCACTA, and APPGAAHYrev, 5'-CGTAGTGGGCGGCGCCGGGGGGG (remnants of NarI site underlined), and cloned in between the N-terminal signal sequence and the mature EPO coding region.

## f) Cell culture procedures

The mutagenized cell line CHO/dhfr- (ATCC CRL-9096) deficient in the *dhfr* enzyme gene was obtained from the American Type Tissue Collection (Manassas, VA, USA). Untransfected cells were cultured in  $\alpha$ -MEM, 5% dialyzed fetal calf serum (FCS), 2 mM glutamine. Cells were transfected with the EPO plasmids using the FuGENE 6 transfection reagent. Transfected cells were selected in  $\alpha$ -MEM lacking nucleosides ( $\alpha$ -MEM<sup>-</sup>), supplemented with 10% dialysed FCS, 2 mM glutamine. Single colonies were isolated by FACS, expanded, and the culture supernatants were assayed for production and secretion of EPO by enzyme linked immunosorbant assay (ELISA). The EPO expression levels were enhanced several times by the amplification of the *dhfr* and *EPO* genes in

- 20 -

culture media containing increased concentrations of methotrexate (MTX, Sigma Chemical Co., St. Louis, MO, USA).

## (2) Fermentation

5 In the following the fermentation and purification of a modified EPO is described.

### Inoculum Preparation and Fermentation

One vial of the Cell Bank, originating from an modified EPO-producing CHO cell line (Host cell line: ATCC CRL-9096, deficient in the *dhfr* enzyme gene) is taken from the vapour phase of the liquid nitrogen storage tank. The cells are transferred into glass  
10 spinner flasks and cultivated in a hydrogen carbonate-buffered medium in a humidified CO<sub>2</sub> incubator. Typical serum free media used for the inoculum preparation and fermentation are disclosed in European Patent Application 513 738, to Koch published 12 June 1992, or WO 96/35718, to Burg published 14 November 1996, for example contain as  
15 medium DMEM/F12 (e.g. JRH Biosciences/Hazleton Biologics, Denver, US, order No. 57-736) and additionally sodium hydrogencarbonate, L+glutamine, D+glucose, recombinant insulin, sodium selenite, diaminobutane, hydrocortisone, iron(II) sulfate, asparagine, aspartic acid, serine and a stabilizer for mammalian cells such as e.g. polyvinyl alcohol, methyl cellulose, polydextran, polyethylene glycol, Pluronic F68, plasma expander polygelin (HEMACCEL®) or polyvinyl pyrrolidone (WO 96/35718).

20 The cultures are microscopically checked for the absence of contaminating microorganisms, and the cell densities are determined. These tests are performed at each splitting step.

After the initial growth period, the cell culture is diluted with fresh medium to the starting cell density and undergoes another growth cycle. This procedure is repeated until  
25 a culture volume of approximately 2 l per glass spinner flask has been obtained. After approx. 12 doublings 1 to 5 liter of this culture is available which then is used as inoculum for the 10 l inoculum fermenter.

After 3 - 5 days, the culture in the 10 l fermenter can be used as inoculum for the 100 l inoculum fermenter.

30 After additional 3 - 5 days of cultivation, the culture in the 100 l fermenter can be used as inoculum for a 1000 l production fermenter.

### Harvesting and Cell Separation

A batch refeed process is used, i.e. when the desired cell density is reached, approx. 80 % of the culture is harvested. The remaining culture is replenished with fresh culture medium and cultivated until the next harvest. One production run consists of a maximum of 10 subsequent harvests: 9 partial harvests and 1 overall harvest at the end of fermentation. Harvesting takes place every 3 - 4 days.

The determined harvest volume is transferred into a cooled vessel. The cells are removed by centrifugation or filtration and discarded. The modified EPO containing supernatant of the centrifugation step is in-line filtered and collected in a second cooled vessel. Each harvest is processed separately during purification. A typical purification process of modified EPO-protein is explained in the following.

### (3) Purification of the modified EPOs

A typical process for the purification of EPO-protein is disclosed in WO 96/35718, to Burg published 14 November 1996. The purification process is applicable to modified EPOs and explained in the following:

#### (1) Blue Sepharose Chromatography

Blue Sepharose (Pharmacia) consists of Sepharose beads to the surface of which the Cibacron blue dye is covalently bound. Since modified EPO binds more strongly to Blue Sepharose than most non-proteinaceous contaminants and proteinaceous impurities, modified EPO can be enriched in this step. The elution of the Blue Sepharose column is performed by increasing the salt concentration as well as the pH.

The column is filled with Blue Sepharose, regenerated with NaOH and equilibrated with equilibration buffer (sodium/ calcium chloride and sodium acetate). The acidified and filtered fermenter supernatant is loaded. After completion of the loading, the column is washed first with a buffer similar to the equilibration buffer containing a higher sodium chloride concentration and consecutively with a Tris-base buffer. The product is eluted with a Tris-base buffer and collected in a single fraction.

- 22 -

### (2) Butyl Toyopearl Chromatography

The Butyl Toyopearl 650 C (Toso Haas) is a polystyrene based matrix to which aliphatic butyl-residues are covalently coupled. Since modified EPO binds more strongly to this gel than most of the impurities, it has to be eluted with a buffer containing

5 isopropanol.

The column is packed with Butyl Toyopearl 650 C, regenerated with NaOH, washed with a Tris-base buffer and equilibrated with a Tris-base buffer containing isopropanol.

The Blue Sepharose eluate is adjusted to the concentration of isopropanol in the column equilibration buffer and loaded onto the column. Then the column is washed with

10 equilibration buffer with increased isopropanol concentration. The product is eluted with elution buffer (Tris-base buffer with high isopropanol content) and collected in a single fraction.

### (3) Hydroxyapatite Ultrogel Chromatography

15 The Hydroxyapatite Ultrogel™ (Biosepra) consists of hydroxyapatite which is incorporated in an agarose matrix to improve the mechanical properties. modified EPO has a low affinity to hydroxyapatite and can therefore be eluted at lower phosphate concentrations than protein impurities.

The column is filled with Hydroxyapatite Ultrogel and regenerated with a potassium

20 phosphate/ calcium chloride buffer and NaOH followed by a Tris-base buffer. Then it is equilibrated with a Tris-base buffer containing a low amount of isopropanol and sodium chloride.

The modified EPO containing eluate of the Butyl Toyopearl chromatography is loaded onto the column. Subsequently the column is washed with equilibration buffer and

25 a Tris-base buffer without isopropanol and sodium chloride. The product is eluted with a Tris-base buffer containing a low concentration of potassium phosphate and collected in a single fraction.

The eluate of the Hydroxyapatite Ultrogel column is concentrated and diafiltered against citraconylation buffer. Concentration/diafiltration is performed with a Millipore

30 Labscale™ TFF System fitted with 10 kDa cut off Millipore Pellicon XL membrane.

**EXAMPLE 2: Citraconylation of modified EPO, proteolytic cleavage and purification of the protected EPO.**

The solution of the modified EPO is adjusted to pH 9.0 and stirred at room  
5 temperature. Citraconic anhydride (Merck 8.41321.0100) is added slowly to the stirred  
solution in aliquots; pH of 9.0 is maintained by addition of 1 N NaOH with a pH-stat. The  
total amount of citraconic anhydride corresponds to a 5fold molar excess to the  $\epsilon$ -amino  
groups of lysines in the modified EPO. When the addition of citraconic anhydride is  
completed, the reaction mixture is stirred at room temperature. Residual citraconic  
10 anhydride is removed by addition of 2 M ethanolamine solution, adjusted to pH 9.0.

Cleavage of the modified protected EPO is achieved by addition of the cleavage  
protease. In case of the construct as described in Example 1(1c) Factor Xa (Roche  
Molecular Biochemicals, Order No. 602388) is added to the modified EPO 1 : 100 (w/w)  
and stirred at room temperature for several hours. The progress of cleavage is controlled  
15 by taking samples and assaying for cleavage products. In case of to low splitting rate, the  
amount of the protease can be increased.

In case of applying other proteases, such as IgA protease (prepared as described in  
EP 513,073) and Genenase™ (Genencor Int. Inc.), the procedure is performed accordingly.

The removal of the protease from the reaction mixture is achieved by size exclusion  
20 chromatography (SEC) on Superdex™ 75 pg (Pharmacia).

The Superdex 75 pg material consists of cross-linked agarose and dextran beads.  
After packing, the column is regenerated with NaOH and equilibrated with a phosphate  
buffer system with 100 mM sodium chloride.

The reaction mixture from the previous step is concentrated to 10 mg/ml on a  
25 Millipore Labscale™ TFF System fitted with 10 kDa cut off Millipore Pellicon XL  
membrane. About 1 - 5 % of the column volume of this solution is applied to the column  
in one step. The chromatography is performed in the equilibration buffer system. The  
product is collected in fractions which are pooled according to their purity as analyzed by  
analytical rpHPLC.

30 The pooled fractions are concentrated to 7-8 mg/ml on a Millipore Labscale™ TFF  
System fitted with 10 kDa cut off Millipore Pellicon XL membrane.

### EXAMPLE 3: Preparation of N-terminally pegylated EPO

The pegylation reaction is performed at a molar ratio of 1:5 (protected EPO to PEG-SBA reagent) at a final protein concentration of 5 mg/ml. The pegylation reagent used is a  
5 methoxy-PEG-SBA, which is a compound of Formula II in which R is methyl; x is 3; and m is from 650 to 750 (average about 730, corresponding to an average molecular weight of about 32 kDa).

The 30 kDa PEG-SBA (Shearwater Polymers, Inc.) is dissolved in 1 mM HCl. Enough 100 mM potassium phosphate buffer, pH 7.5, is added to get a final phosphate  
10 concentration of 20 mM in the reaction mixture. The reaction mixture is stirred at ambient temperature (20 - 25°C). After 2 h the reaction is stopped by adjusting the pH to 2.5 with acid.

Decitraconylation of the protein is achieved by stirring the solution at a pH of 2.5 for 5 h at ambient temperature. The reaction is stopped by adjusting the pH to 4.5 with  
15 sodium hydroxide and the solution is stored frozen at -20°C until ready for purification.

The separation of N-terminal pegylated EPO (PEG-A1-EPO) from excess reagents, reaction byproducts and un-pegylated EPO is achieved by chromatography on SP-Sepharose FF (Pharmacia). The SP-Sepharose material consists of sulfopropyl (SP)-groups which are covalently bound to the surface of Sepharose beads. The column is filled with  
20 SP-Sepharose and regenerated with phosphoric acid and NaOH and equilibrated with a sodium acetate buffer.

The reaction mixture from the previous step is diluted 1:5 with sodium acetate buffer, pH 4.5 and applied to the SP-Sepharose column. The column is washed with equilibration buffer to remove excess reagents and reaction byproducts. It is followed by  
25 washing with 100 mM NaCl. PEG-A1-EPO is then eluted with 200 mM NaCl. The product is collected in fractions which are pooled according to their purity as determined by high performance Size Exclusion Chromatography. Un-pegylated EPO remaining on the column is eluted with 750 mM NaCl.

The PEG-A1 EPO pool is then concentrated to ~ 4.5 – 7.5 mg/ml and diafiltered into  
30 the storage buffer, 10 mM potassium phosphate, 100 mM NaCl, pH 7.5. Concentration/Diafiltration was performed with Millipore Labscale™ TFF System fitted

- 25 -

with 10 kDa cut off Millipore Pellicon XL Biomax membrane at ambient temperature. Concentrated PEG-A1 EPO is sterile filtered and stored frozen at -20°C.

Approximately 95% of EPO is pegylated..

#### 5 EXAMPLE 4: In-vivo activity of PEG-A1-EPO determined by the normocythaemic mouse assay

The normocythaemic mouse bioassay is known in the art (Pharm. Europa Spec. Issue Erythropoietin BRP Bio 1997(2)) and a method in the monography of erythropoietin of Ph. Eur. BRP. The samples are diluted with BSA-PBS. Normal healthy mice, 7-15 weeks old, are administered s.c. 0.2 ml of the PEG-A1-EPO-solution from Examples 1-3, EPO solution and buffer as control. Over a period of 6 days, blood is drawn by puncture of the tail vein and diluted such that 1 µl of blood is present in 1 ml of an 0.15 µmol acridine orange staining solution. The staining time is 3 to 10 minutes. The reticulocyte counts are carried out microfluorometrically in a flow cytometer by analysis of the red fluorescence histogram. The reticulocyte counts are given in terms of absolute figures (per 30,000 blood cells analyzed). For the data presented, each group consisted of 5 mice per day, and the mice were bled only once.

The results are shown in Table 1.

The results show the superior activity and the prolonged half life of PEG-A1-EPO species indicated by the significantly increased amounts of reticulocytes and the shift of the reticulocytes count maximum using the same dose per mouse (100 ng), compared to EPO derived from CHO cells.

Table 1

	EPO	PEG-A1-EPO	Control Buffer
72h	2404	2911	857
96h	1814	3713	697
120h	901	not measured	701
144h	536	3424	708

5

DESCRIPTION OF THE DRAWINGS

Figure 1: Primary structure of human EPO (165 amino acids).

Figure 2: Primary structure of human EPO (166 amino acids).

10      Figure 3: Primary structure and corresponding nucleic acid sequence of the APPRIEGR-EPO. The underlined amino acid sequence corresponds to the secretion signal sequence, the wave line to the amino acid sequence specific for the proteolytic cleavage site.


15      Figure 4: Primary structure and corresponding nucleic acid sequence of APP-EPO. The underlined amino acid sequence corresponds to the secretion signal sequence, the wave line to the amino acid sequence specific for the proteolytic cleavage site.

20      Figure 5: Primary structure and corresponding nucleic acid sequence of APPGAAHY-EPO. The underlined amino acid sequence corresponds to the secretion signal sequence, the wave line to the amino acid sequence specific for the proteolytic cleavage site.



CLAIMS

1. A conjugate, said conjugate comprising an erythropoietin glycoprotein having an N-terminal  $\alpha$ -amino group and having the *in vivo* biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula




with the -CO of the poly(ethylene glycol) group forming an amide bond with said N-terminal  $\alpha$ -amino group; wherein

R is lower alkyl;

x is 2 or 3; and

m is from about 450 to about 1350.

2. The conjugate of claim 1, of the formula:



wherein x, m and R are as defined in claim 1, and P is the residue of the glycoprotein without the N-terminal  $\alpha$ -amino group which forms an amide linkage with the poly(ethylene glycol) group.

3. The conjugate of any preceding claim, wherein R is methyl.
4. The conjugate of any preceding claim, wherein m is from 550 to 1000.
5. The conjugate of any preceding claim, wherein m is from about 650 to about 750.
6. The conjugate of any preceding claim, wherein R is methyl and m is from about 650 to about 750.
7. The conjugate of any preceding claim having the formula

- 28 -



wherein m is from 650 to 750 and P is as defined in claim 2.


8. The conjugate of any preceding claim, wherein the glycoprotein is a human erythropoietin.
9. The conjugate according to any of claims 1 to 7, wherein the human erythropoietin glycoprotein is expressed by endogenous gene activation.
10. The conjugate according to any of claims 1 to 9, wherein the glycoprotein has the sequence shown in Fig. 1 or Fig. 2.
11. The conjugate according to any of claims 1 to 8, wherein the glycoprotein has the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites.
12. The conjugate according to any of claims 1 to 11, wherein the glycoprotein has the sequence of human erythropoietin modified by a modification selected from the group consisting of:
  - Asn<sup>30</sup>Thr<sup>32</sup>;
  - Asn<sup>51</sup>Thr<sup>53</sup>;
  - Asn<sup>57</sup>Thr<sup>59</sup>;
  - Asn<sup>69</sup>;
  - Asn<sup>69</sup>Thr<sup>71</sup>;
  - Ser<sup>68</sup>Asn<sup>69</sup>Thr<sup>71</sup>;
  - Val<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;
  - Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;
  - Ser<sup>87</sup>Asn<sup>88</sup>Gly<sup>89</sup>Thr<sup>90</sup>;
  - Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>Thr<sup>92</sup>;
  - Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>Ala<sup>162</sup>;
  - Asn<sup>69</sup>Thr<sup>71</sup>Ser<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;
  - Asn<sup>30</sup>Thr<sup>32</sup>Val<sup>87</sup>Asn<sup>88</sup>Thr<sup>90</sup>;
  - Asn<sup>89</sup>Ile<sup>90</sup>Thr<sup>91</sup>;
  - Ser<sup>87</sup>Asn<sup>89</sup>Ile<sup>90</sup>Thr<sup>91</sup>;
  - Asn<sup>136</sup>Thr<sup>138</sup>;
  - Asn<sup>138</sup>Thr<sup>140</sup>;
  - Thr<sup>125</sup>; and

- 29 -

Pro<sup>124</sup>Thr<sup>125</sup>.

13. The conjugate according to any of claims 1 to 7, wherein the glycoprotein has the  
5 sequence of human erythropoietin modified by a rearrangement of at least one  
glycosylation site.
14. The conjugate of claim 13, wherein the rearrangement comprises deletion of any of  
10 the N-linked glycosylation sites in human erythropoietin and addition of an N-  
linked glycosylation site at position 88 of the sequence of human erythropoietin.
15. The conjugate of claim 14, wherein the glycoprotein has the sequence of human  
erythropoietin modified by a modification selected from the group consisting of:  
15 Gln<sup>24</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>;  
Gln<sup>38</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>; and  
Gln<sup>83</sup> Ser<sup>87</sup> Asn<sup>88</sup> Thr<sup>90</sup>.
16. A pharmaceutical composition comprising a conjugate as defined in any of claims 1  
to 15 and a pharmaceutically acceptable excipient.  
20
17. Use of a conjugate according to any of claims 1 to 15 for the preparation of  
medicaments.
18. Use of a conjugate according to any of claims 1 to 15 for the treatment or  
25 prophylaxis of diseases correlated with anemia in chronic renal failure patients  
(CRF), AIDS and for the treatment of cancer patients undergoing chemotherapy.
19. A method for the prophylactic and/or therapeutic treatment of disorders involving  
anemia in chronic renal failure patients (CRF), AIDS and cancer patients  
30 undergoing chemotherapy comprising the step of administering to a patient a  
conjugate as claimed in any one of claims 1 to 15.
20. A process for the preparation of a conjugate as defined in any of claims 1 to 15,  
comprising  
35 a) expression, and preferably serumfree fermentation, of a recombinant EPO  
protein comprising a N-terminal peptidic extension which comprises a  
proteolytic cleavage sequence

- b) protecting the  $\epsilon$ -amino groups,
  - c) proteolytic cleavage of the N-terminal peptidic extension,
  - d) pegylation of the N-terminal  $\alpha$ -amino group,
  - e) deprotection of the  $\epsilon$ -amino groups of the erythropoietin glycoprotein,
  - f) wherein optionally each of the above steps may be followed by a purification step.
21. The process of claim 20 wherein the recombinant EPO comprises a sequence selected from the group consisting of the amino acid sequences shown in Fig. 1 to 5.
  22. The process according to claim 20 or 21 wherein in step b) the  $\epsilon$ -amino groups are protected by a citraconylation.
  23. The process according to any of claims 20 to 23 wherein the N-terminal  $\alpha$ -amino group is pegylated with



in which R and m are as defined in any of claims 1 to 15.

- 15 24. Compounds according to any of claims 1 to 15, whenever prepared by the process according to claims 20 to 23.
25. Compounds according to any of claims 1 to 15 for the treatment of diseases which are associated with anemia in chronic renal failure patients (CRF), AIDS and cancer patients undergoing chemotherapy.
- 20 26. Erythropoietin glycoproteins comprising the amino acid sequences as shown in Fig. 1 and Fig. 2 having a N-terminal peptidic extension which represents a proteolytic cleavage site, optionally comprising a N-terminal purification tag.
27. The novel compounds, processes and methods as well as the use of such compounds substantially as described hereinbefore.

- 31 -

EPO - Munich  
3ABSTRACT

20. Dez. 2000

The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal  $\alpha$ -amino group  
5 and having the *in vivo* biological activity of causing bone marrow cells to increase  
production of reticulocytes and red blood cells and selected from the group consisting of  
human erythropoietin and analogs thereof which have sequence of human erythropoietin  
modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least  
one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene  
10 glycol) group of the formula



with the -CO of the poly(ethylene glycol) group forming an amide bond with said N-  
terminal  $\alpha$ -amino group; wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to  
about 1350.

15



EPO - Munich  
3

20. Dez. 2000

**Fig. 1**

[illegible]

- 33 -

**Fig. 2**

5    Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu  
       1                  5                  10                  15  
       Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His  
                   20                  25                  30  
 10    Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe  
                   35                  40                  45  
       Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp  
 15           50                  55                  60  
       Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu  
           65                  70                  75                  80  
 20    Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp  
                   85                  90                  95  
       Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu  
                   100                  105                  110  
 25    Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala  
           115                  120                  125  
       Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val  
 30           130                  135                  140  
       Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala  
       145                  150                  155                  160  
 35    Cys Arg Thr Gly Asp Arg  
                   165



- 34 -

Fig. 3

5  
1 GGAATTCACCACCATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCT  
-----+-----+-----+-----+-----+-----+ 60  
CCTTAAGTGGTGGTACCCCCACGTGCTTACAGGACGGACCGACACCGAAGAGGACAGGGA  
M G V H E C P A W L W L L L S L -

10  
61 GCTGTGCTCCCTCTGGGCCTCCCAGTCCTGGGCGCCCCCCCCGAATCGAGGGCCGCGC  
-----+-----+-----+-----+-----+-----+ 120  
CGACACGAGGGAGACCCGAGGGTCAGGACCCGCGGGGGGGGGCTTAGCTCCCGGCGCG  
L S L P L G L P V L G A P P R I E G R A -

15  
121 CCCACCACGCCTCATCTGTGACAGCCGAGTCCTGGAGAGGTACCTCTTGAGGGCCAAGGA  
-----+-----+-----+-----+-----+-----+ 180  
GGGTGGTGGGAGTAGACACTGTGGCTCAGGACCTCTCCATGGAGAACCTCCGGTTCT  
P P R L I C D S R V L E R Y L L E A K E -

20  
181 GGCCGAGAATATCACGACGGGCTGTGCTGAACACTGCAGCTTGAATGAGAATATCACTGT  
-----+-----+-----+-----+-----+-----+ 240  
CCGGCTCTTATAGTGCTGCCGACACGACTTGTGACGTGCAACTTACTCTTATAGTGACA  
A E N I T T G C A E H C S L N E N I T V -

25  
241 CCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAGGATGGAGGTGCGGCAGCAGGCCGT  
-----+-----+-----+-----+-----+-----+ 300  
GGGTCTGTGGTTTCAATTAAGATACGGACCTTCTCCTACCTCCAGCCCGTCGTCCGGCA  
P D T K V N F Y A W K R M E V G Q Q A V -

30  
301 AGAAGTCTGGCAGGGCCTGGCCCTGCTGTGCGGAAGCTGTCCTGCGGGGCCAGGCCCTGTT  
-----+-----+-----+-----+-----+-----+ 360  
TCTTCAGACCGTCCCGGACCGGGACGACAGCCTTCGACAGGACGCCCCGGTCCGGGACAA  
E V W Q G L A L L S E A V L R G Q A L L -

35  
361 GGTCAACTCTTCCCAGCCGTGGGAGCCCCTGCAGCTGCATGTGGATAAAGCCGTCAGTGG  
-----+-----+-----+-----+-----+-----+ 420  
CCAGTTGAGAAGGGTCGGCACCCCTCGGGGACGTGACGTACACCTATTTCCGGCAGTCACC  
V N S S Q P W E P L Q L H V D K A V S G -

40  
421 CCTTCGCAGCCTCACCCTCTGCTTCGGGCTCTGGGAGCCAGAAGGAAGCCATCTCCCC  
-----+-----+-----+-----+-----+-----+ 480  
GGAAGCGTCGGAGTGGTGAGACGAAGCCCGAGACCTCGGGTCTTCCTTCGGTAGAGGGG  
L R S L T T L L R A L G A Q K E A I S P -

45  
481 TCCAGATGCGGCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTTCCGCAAAC  
-----+-----+-----+-----+-----+-----+ 540  
AGGTCTACGCCGAGTCGACGAGGTGAGGCTTGTTAGTGACGACTGTGAAAGGCGTTTGA  
P D A A S A A P L R T I T A D T F R K L -

50  
541 CTCCGAGTCTACTCCAATTTCTCCGGGGAAGCTGAAGCTGTACACAGGGGAGGCCTG  
-----+-----+-----+-----+-----+-----+ 600  
GAAGGCTCAGATGAGGTAAAGGAGGCCCTTTGACTTCGACATGTGTCCCCTCCGGAC  
F R V Y S N F L R G K L K L Y T G E A C -

55  
601 CAGGACAGGGGACAGATGACCAGGTGAC  
-----+-----+-----+-----+-----+ 629  
GTCCTGTCCCCTGTCTACTGGTCCAGCTG  
R T G D R \* -

Fig. 4

5 1 GGAATTCACCACCATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCT  
-----+-----+-----+-----+-----+ 60  
CCTTAAGTGGTGGTACCCCCACGTGCTTACAGGACGGACCGACACCGAAGAGGACAGGGA  
M G V H E C P A W L W L L L S L -

10 61 GCTGTCGCTCCCTCTGGGCCTCCCAGTCCTGGGCGCCCCCGCCCCACCACGCCTCAT  
-----+-----+-----+-----+-----+ 120  
CGACAGCGAGGGAGACCCGGAGGGTCAGGACCCGCGGGGGGGCGGGGTGGTGCAGGTA  
L S L P L G L P V L G A P P A P P R L I -

15 121 CTGTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGAGGCCGAGAATATCAC  
-----+-----+-----+-----+-----+ 180  
GACACTGTGCGCTCAGGACCTCTCCATGGAGAACCTCCGGTTCCTCCGGCTCTTATAGTG  
C D S R V L E R Y L L E A K E A E N I T -

20 181 GACGGGCTGTGCTGAACACTGCAGCTTGAATGAGAATATCACTGTCCCAGACACCAAAGT  
-----+-----+-----+-----+-----+ 240  
CTGCCCCGACACGACTTGTGACGTGAACTTACTCTTATAGTGACAGGGTCTGTGGTTTCA  
T G C A E H C S L N E N I T V P D T K V -

25 241 TAATTTCTATGCCTGGAAGAGGATGGAGGTGCGGCAGCAGGCCGTAGAAGTCTGGCAGGG  
-----+-----+-----+-----+-----+ 300  
ATTAAAGATACGGACCTTCTCCTACCTCCAGCCCGTCGTCCGGCATCTTCAGACCGTCCC  
N F Y A W K R M E V G Q Q A V E V W Q G -

30 301 CCTGGCCCTGCTGTGCGAAGCTGTCCTGCGGGGCCAGGCCCTGTTGGTCAACTCTTCCCA  
-----+-----+-----+-----+-----+ 360  
GGACCGGGACGACAGCCTTCGACAGGACGCCCCGGTCCGGGACAACCAGTTGAGAAGGGT  
L A L L S E A V L R G Q A L L V N S S Q -

35 361 GCGGTGGGAGCCCTGCAGCTGCATGTGGATAAAGCCGTCAGTGGCCTTCGACGCTCAC  
-----+-----+-----+-----+-----+ 420  
CGGCACCCTCGGGGACGTGACGTACACCTATTTGCGCAGTCACCGGAAGCGTCGGAGTG  
P W E P L Q L H V D K A V S G L R S L T -

40 421 CACTCTGCTTCGGGCTCTGGGAGCCCAGAAGGAAGCCATCTCCCCTCCAGATGCGGCCTC  
-----+-----+-----+-----+-----+ 480  
GTGAGACGAAGCCCAGACCCCTCGGGTCTTCTTCGGTAGAGGGGAGGTCTACGCCGGAG  
T L L R A L G A Q K E A I S P P D A A S -

45 481 AGCTGCTCCACTCCGAACAATCACTGCTGACACTTTCCGAAACTCTTCCGAGTCTACTC  
-----+-----+-----+-----+-----+ 540  
TCGACGAGGTGAGGCTTGTTAGTGACGACTGTGAAAGGCGTTTGAGAAGGCTCAGATGAG  
A A P L R T I T A D T F R K L F R V Y S -

50 541 CAATTTCTCCTCGGGGAAAGCTGAAGCTGTACACAGGGGAGGCTGCAGGACAGGGGACAG  
-----+-----+-----+-----+-----+ 600  
GTTAAAGGAGGCCCTTTGCACTTCGACATGTGTCCCCTCCGGACGTCCTGTCCCTGTC  
N F L R G K L K L Y T G E A C R T G D R -

55 601 ATGACCAGGTCGAC  
-----+----- 614  
TACTGGTCCAGCTG  
\*

- 36 -

Fig. 5

```

5      GGAATTCACCACCATGGGGGTGCACGAATGTCCTGCCTGGCTGTGGCTTCTCCTGTCCCT
      1  -----+-----+-----+-----+-----+-----+ 60
      CCTTAAGTGGTGGTACCCCCACGTGCTTACAGGACGGACCGACACCGAAGAGGACAGGGA
           M G V H E C P A W L W L L L S L -
10     GCTGTCGCTCCCTCTGGGCCTCCCAGTCCTGGGCGCCCCCCCCGGCGCCGCCCACTACGC
      61  -----+-----+-----+-----+-----+-----+ 120
      CGACAGCGAGGGAGACCCGGAGGGTCAGGACCCGCGGGGGGGGCGCGGCGGGTGATGCG
      L S L P L G L P V L G A P P G A A H Y A -
15     CCCACCACGCCTCATCTGTGACAGCCGAGTCCTGGAGAGGTACCTCTTGGAGGCCAAGGA
      121 -----+-----+-----+-----+-----+-----+ 180
      GGGTGGTGGGAGTAGACACTGTGCGCTCAGGACCTCTCCATGGAGAACCTCCGGTTCCT
      P P R L I C D S R V L E R Y L L E A K E -
20     GGCCGAGAATATCACGACGGGCTGTGCTGAACACTGCAGCTTGAATGAGAATATCACTGT
      181 -----+-----+-----+-----+-----+-----+ 240
      CCGGCTCTTATAGTGCTGCCCGACACGACTTGTGACGTGGAACCTTACTTTATAGTGACA
      A E N I T T G C A E H C S L N E N I T V -
25     CCCAGACACCAAAGTTAATTTCTATGCCTGGAAGAGGATGGAGGTGCGGCAGCAGGCCGT
      241 -----+-----+-----+-----+-----+-----+ 300
      GGGTCTGTGGTTTCAATTAAGATACGGACCTTCTCCTACCTCCAGCCCGTCGTCCGGCA
      P D T K V N F Y A W K R M E V G Q Q A V -
30     AGAAGTCTGGCAGGGCCTGGCCCTGCTGTGCGGAAGCTGTCTGCGGGGCCAGGCCCTGTT
      301 -----+-----+-----+-----+-----+-----+ 360
      TCTTCAGACCGTCCCGGACCGGGACGACAGCCTTCGACAGGACGCCCGGTCCGGGACAA
      E V W Q G L A L L S E A V L R G Q A L L -
35     GGTCAACTCTTCCAGCCGTGGGAGCCCTGCAGCTGCATGTGGATAAAGCCGTCAGTGG
      361 -----+-----+-----+-----+-----+-----+ 420
      CCAGTTGAGAAGGGTCGGCACCTCGGGGACGTGACGTACACCTATTTCCGGCAGTCACC
      V N S S Q P W E P L Q L H V D K A V S G -
40     CCTTCGCAGCCTCACCCTCTGCTTCGGGCTCTGGGAGCCCAGAAGGAAGCCATCTCCCC
      421 -----+-----+-----+-----+-----+-----+ 480
      GGAAGCGTCGGAGTGGTGAGACGAAGCCCGAGACCTCGGGTCTTCCTTCGGTAGAGGGG
      L R S L T T L L R A L G A Q K E A I S P -
45     TCCAGATGCGGCCTCAGCTGCTCCACTCCGAACAATCACTGCTGACACTTTCCGCAAAC
      481 -----+-----+-----+-----+-----+-----+ 540
      AGGTCTACGCCGGAGTCGACGAGGTGAGGCTTGTTAGTGACGACTGTGAAAGGCGTTTGA
      P D A A S A A P L R T I T A D T F R K L -
50     CTTCCGAGTCTACTCCAATTTCTCCGGGGAAGCTGAAGCTGTACACAGGGGAGGCCTG
      541 -----+-----+-----+-----+-----+-----+ 600
      GAAGGCTCAGATGAGGTTAAAGAGGCCCCCTTCGACTTCGACATGTGTCCCCTCCGGAC
      F R V Y S N F L R G K L K L Y T G E A C -
55     CAGGACAGGGGACAGATGACCAGGTCGAC
      601 -----+-----+-----+-----+-----+ 629
      GTCCTGTCCCCTGTCTACTGGTCCAGCTG
      R T G D R *

```

